Table 5.

Antibacterial Activities Of CAZ/AVI And ATM/AVI Against 58 CRE Bacteremic Isolates

Resistance Mechanisms	MIC of CAZ/AVI (μg/mL)
0.125/4	0.25/4	0.5/4	1/4	2/4	4/4	8/4	16/4	32/4	64/4	>64/4
Carbapenemase positive
NDM-1, ESBLs, OMP loss or deficiency	0	0	0	0	0	0	0	1	2	0	1
NDM-5, ESBLs, OMP loss or deficiency	0	0	0	0	0	0	0	1	3	0	1
KPC-2, ESBLs, OMP loss or deficiency	0	0	1	2	11	11	4	1	0	0	1
IMP-4, ESBLs, OMP deficiency	0	0	0	0	0	0	0	0	0	1	1
IMP-8, ESBLs, OMP loss	0	0	0	0	0	0	0	1	0	0	0
KPC-2, IMP-4, ESBLs, OMP deficiency	0	0	0	0	0	0	0	0	0	0	1
Carbapenemase negative
AmpC, ESBL	1	0	0	0	0	0	0	0	0	0	0
AmpC, OMP loss	0	0	0	0	0	0	1	0	0	0	0
AmpC, ESBLs, OMP loss	0	0	0	0	0	0	0	1	0	0	0
ESBLs, OMP loss or deficiency	0	0	1	1	4	3	1	1	0	0	0
Resistance mechanisms	MIC of ATM/AVI (μg/mL)
0.125/4	0.25/4	0.5/4	1/4	2/4	4/4	8/4	16/4	32/4	64/4	>64/4
Carbapenemase positive
NDM-1, ESBLs, OMP loss or deficiency	0	2	1	0	0	1	0	0	0	0	0
NDM-5, ESBLs, OMP loss or deficiency	1	0	1	1	0	1	1	0	0	0	0
KPC-2, OMP loss or deficiency	3	9	7	8	2	1	1	0	0	0	0
IMP-4, ESBLs, OMP deficiency	0	1	0	1	0	0	0	0	0	0	0
IMP-8, ESBLs, OMP loss	0	1	0	0	0	0	0	0	0	0	0
KPC-2, IMP-4, ESBLs, OMPs deficiency	0	0	0	0	1	0	0	0	0	0
Carbapenemase negative
AmpC, ESBLs	1	0	0	0	0	0	0	0	0	0	0
AmpC, OMP loss	1	0	0	0	0	0	0	0	0	0	0
AmpC, ESBLs, OMP loss	1	0	0	0	0	0	0	0	0	0	0
ESBLs, OMP loss or deficiency	2	5	2	1	1	0	0	0	0	0	0